(Sharecast News) - Shield Therapeutics said the Chinese National Medical Products Administration has accepted a marketing authorisation application for Accrufer, or ferric maltol, for the treatment of iron deficiency in adults.
The AIM-traded firm said the application was filed by Shield's licensing partner, Beijing Aosaikang Pharmaceutical Co, following completion of a...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE